Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.
Identifieur interne : 000291 ( Main/Exploration ); précédent : 000290; suivant : 000292Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.
Auteurs : Walter Gottlieb Land [France, Allemagne]Source :
- Molecular diagnosis & therapy [ 1179-2000 ] ; 2020.
Descripteurs français
- KwdFr :
- Acides nucléiques acellulaires (sang), Homéostasie (MeSH), Humains (MeSH), Immunité innée (effets des médicaments et des substances chimiques), Immunité innée (physiologie), Infections à coronavirus (traitement médicamenteux), Inflammation (métabolisme), Inflammation (traitement médicamenteux), Maladie chronique (MeSH), Marqueurs biologiques (sang), Molécules contenant des motifs associés aux pathogènes (métabolisme), Protéine HMGB1 (sang), Protéines S100 (sang), Thérapie moléculaire ciblée (méthodes), Vaccination (MeSH).
- MESH :
- effets des médicaments et des substances chimiques : Immunité innée.
- métabolisme : Inflammation, Molécules contenant des motifs associés aux pathogènes.
- méthodes : Thérapie moléculaire ciblée.
- physiologie : Immunité innée.
- sang : Acides nucléiques acellulaires, Marqueurs biologiques, Protéine HMGB1, Protéines S100.
- traitement médicamenteux : Infections à coronavirus, Inflammation.
- Homéostasie, Humains, Maladie chronique, Vaccination.
English descriptors
- KwdEn :
- Biomarkers (blood), Cell-Free Nucleic Acids (blood), Chronic Disease (MeSH), Coronavirus Infections (drug therapy), HMGB1 Protein (blood), Homeostasis (MeSH), Humans (MeSH), Immunity, Innate (drug effects), Immunity, Innate (physiology), Inflammation (drug therapy), Inflammation (metabolism), Molecular Targeted Therapy (methods), Pathogen-Associated Molecular Pattern Molecules (metabolism), S100 Proteins (blood), Vaccination (MeSH).
- MESH :
- chemical , blood : Biomarkers, Cell-Free Nucleic Acids, HMGB1 Protein, S100 Proteins.
- drug effects : Immunity, Innate.
- drug therapy : Coronavirus Infections, Inflammation.
- metabolism : Inflammation, Pathogen-Associated Molecular Pattern Molecules.
- methods : Molecular Targeted Therapy.
- physiology : Immunity, Innate.
- Chronic Disease, Homeostasis, Humans, Vaccination.
Abstract
This opinion article discusses the increasing attention paid to the role of activating damage-associated molecular patterns (DAMPs) in initiation of inflammatory diseases and suppressing/inhibiting DAMPs (SAMPs) in resolution of inflammatory diseases and, consequently, to the future roles of these novel biomarkers as therapeutic targets and therapeutics. Since controlled production of DAMPs and SAMPs is needed to achieve full homeostatic restoration and repair from tissue injury, only their pathological, not their homeostatic, concentrations should be therapeutically tackled. Therefore, distinct caveats are proposed regarding choosing DAMPs and SAMPs for therapeutic purposes. For example, we discuss the need to a priori identify and define a context-dependent "homeostatic DAMP:SAMP ratio" in each case and a "homeostatic window" of DAMP and SAMP concentrations to guarantee a safe treatment modality to patients. Finally, a few clinical examples of how DAMPs and SAMPs might be used as therapeutic targets or therapeutics in the future are discussed, including inhibition of DAMPs in hyperinflammatory processes (e.g., systemic inflammatory response syndrome, as currently observed in Covid-19), administration of SAMPs in chronic inflammatory diseases, inhibition of SAMPs in hyperresolving processes (e.g., compensatory anti-inflammatory response syndrome), and administration/induction of DAMPs in vaccination procedures and anti-cancer therapy.
DOI: 10.1007/s40291-020-00460-z
PubMed: 32248387
PubMed Central: PMC7127836
Affiliations:
- Allemagne, France
- Alsace (région administrative), Bavière, District de Haute-Bavière, Grand Est
- Munich, Strasbourg
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.</title><author><name sortKey="Land, Walter Gottlieb" sort="Land, Walter Gottlieb" uniqKey="Land W" first="Walter Gottlieb" last="Land">Walter Gottlieb Land</name><affiliation wicri:level="3"><nlm:affiliation>Molecular ImmunoRheumatology, INSERM UMR_S1109, Laboratory of Excellence Transplantex, University of Strasbourg, Strasbourg, France. land.w.damps@gmail.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Molecular ImmunoRheumatology, INSERM UMR_S1109, Laboratory of Excellence Transplantex, University of Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>German Academy for Transplantation Medicine, Munich, Germany. land.w.damps@gmail.com.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Academy for Transplantation Medicine, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32248387</idno><idno type="pmid">32248387</idno><idno type="doi">10.1007/s40291-020-00460-z</idno><idno type="pmc">PMC7127836</idno><idno type="wicri:Area/Main/Corpus">001797</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001797</idno><idno type="wicri:Area/Main/Curation">001797</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001797</idno><idno type="wicri:Area/Main/Exploration">001797</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.</title><author><name sortKey="Land, Walter Gottlieb" sort="Land, Walter Gottlieb" uniqKey="Land W" first="Walter Gottlieb" last="Land">Walter Gottlieb Land</name><affiliation wicri:level="3"><nlm:affiliation>Molecular ImmunoRheumatology, INSERM UMR_S1109, Laboratory of Excellence Transplantex, University of Strasbourg, Strasbourg, France. land.w.damps@gmail.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Molecular ImmunoRheumatology, INSERM UMR_S1109, Laboratory of Excellence Transplantex, University of Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>German Academy for Transplantation Medicine, Munich, Germany. land.w.damps@gmail.com.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>German Academy for Transplantation Medicine, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author></analytic><series><title level="j">Molecular diagnosis & therapy</title><idno type="eISSN">1179-2000</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biomarkers (blood)</term><term>Cell-Free Nucleic Acids (blood)</term><term>Chronic Disease (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>HMGB1 Protein (blood)</term><term>Homeostasis (MeSH)</term><term>Humans (MeSH)</term><term>Immunity, Innate (drug effects)</term><term>Immunity, Innate (physiology)</term><term>Inflammation (drug therapy)</term><term>Inflammation (metabolism)</term><term>Molecular Targeted Therapy (methods)</term><term>Pathogen-Associated Molecular Pattern Molecules (metabolism)</term><term>S100 Proteins (blood)</term><term>Vaccination (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acides nucléiques acellulaires (sang)</term><term>Homéostasie (MeSH)</term><term>Humains (MeSH)</term><term>Immunité innée (effets des médicaments et des substances chimiques)</term><term>Immunité innée (physiologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Inflammation (métabolisme)</term><term>Inflammation (traitement médicamenteux)</term><term>Maladie chronique (MeSH)</term><term>Marqueurs biologiques (sang)</term><term>Molécules contenant des motifs associés aux pathogènes (métabolisme)</term><term>Protéine HMGB1 (sang)</term><term>Protéines S100 (sang)</term><term>Thérapie moléculaire ciblée (méthodes)</term><term>Vaccination (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term><term>Cell-Free Nucleic Acids</term><term>HMGB1 Protein</term><term>S100 Proteins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Immunity, Innate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Immunité innée</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Inflammation</term><term>Pathogen-Associated Molecular Pattern Molecules</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Molecular Targeted Therapy</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Inflammation</term><term>Molécules contenant des motifs associés aux pathogènes</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Thérapie moléculaire ciblée</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Immunité innée</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Immunity, Innate</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Acides nucléiques acellulaires</term><term>Marqueurs biologiques</term><term>Protéine HMGB1</term><term>Protéines S100</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Inflammation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Chronic Disease</term><term>Homeostasis</term><term>Humans</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Homéostasie</term><term>Humains</term><term>Maladie chronique</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This opinion article discusses the increasing attention paid to the role of activating damage-associated molecular patterns (DAMPs) in initiation of inflammatory diseases and suppressing/inhibiting DAMPs (SAMPs) in resolution of inflammatory diseases and, consequently, to the future roles of these novel biomarkers as therapeutic targets and therapeutics. Since controlled production of DAMPs and SAMPs is needed to achieve full homeostatic restoration and repair from tissue injury, only their pathological, not their homeostatic, concentrations should be therapeutically tackled. Therefore, distinct caveats are proposed regarding choosing DAMPs and SAMPs for therapeutic purposes. For example, we discuss the need to a priori identify and define a context-dependent "homeostatic DAMP:SAMP ratio" in each case and a "homeostatic window" of DAMP and SAMP concentrations to guarantee a safe treatment modality to patients. Finally, a few clinical examples of how DAMPs and SAMPs might be used as therapeutic targets or therapeutics in the future are discussed, including inhibition of DAMPs in hyperinflammatory processes (e.g., systemic inflammatory response syndrome, as currently observed in Covid-19), administration of SAMPs in chronic inflammatory diseases, inhibition of SAMPs in hyperresolving processes (e.g., compensatory anti-inflammatory response syndrome), and administration/induction of DAMPs in vaccination procedures and anti-cancer therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32248387</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-2000</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>06</Month></PubDate></JournalIssue><Title>Molecular diagnosis & therapy</Title><ISOAbbreviation>Mol Diagn Ther</ISOAbbreviation></Journal><ArticleTitle>Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.</ArticleTitle><Pagination><MedlinePgn>251-262</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40291-020-00460-z</ELocationID><Abstract><AbstractText>This opinion article discusses the increasing attention paid to the role of activating damage-associated molecular patterns (DAMPs) in initiation of inflammatory diseases and suppressing/inhibiting DAMPs (SAMPs) in resolution of inflammatory diseases and, consequently, to the future roles of these novel biomarkers as therapeutic targets and therapeutics. Since controlled production of DAMPs and SAMPs is needed to achieve full homeostatic restoration and repair from tissue injury, only their pathological, not their homeostatic, concentrations should be therapeutically tackled. Therefore, distinct caveats are proposed regarding choosing DAMPs and SAMPs for therapeutic purposes. For example, we discuss the need to a priori identify and define a context-dependent "homeostatic DAMP:SAMP ratio" in each case and a "homeostatic window" of DAMP and SAMP concentrations to guarantee a safe treatment modality to patients. Finally, a few clinical examples of how DAMPs and SAMPs might be used as therapeutic targets or therapeutics in the future are discussed, including inhibition of DAMPs in hyperinflammatory processes (e.g., systemic inflammatory response syndrome, as currently observed in Covid-19), administration of SAMPs in chronic inflammatory diseases, inhibition of SAMPs in hyperresolving processes (e.g., compensatory anti-inflammatory response syndrome), and administration/induction of DAMPs in vaccination procedures and anti-cancer therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Land</LastName><ForeName>Walter Gottlieb</ForeName><Initials>WG</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0090-0629</Identifier><AffiliationInfo><Affiliation>Molecular ImmunoRheumatology, INSERM UMR_S1109, Laboratory of Excellence Transplantex, University of Strasbourg, Strasbourg, France. land.w.damps@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Academy for Transplantation Medicine, Munich, Germany. land.w.damps@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Mol Diagn Ther</MedlineTA><NlmUniqueID>101264260</NlmUniqueID><ISSNLinking>1177-1062</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073888">Cell-Free Nucleic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C585491">HMGB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000069452">Pathogen-Associated Molecular Pattern Molecules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009418">S100 Proteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073888" MajorTopicYN="N">Cell-Free Nucleic Acids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069452" MajorTopicYN="N">Pathogen-Associated Molecular Pattern Molecules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009418" MajorTopicYN="N">S100 Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32248387</ArticleId><ArticleId IdType="doi">10.1007/s40291-020-00460-z</ArticleId><ArticleId IdType="pii">10.1007/s40291-020-00460-z</ArticleId><ArticleId IdType="pmc">PMC7127836</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Front Pharmacol. 2019 Mar 07;10:169</Citation><ArticleIdList><ArticleId IdType="pubmed">30899221</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicina (Kaunas). 2019 Jun 18;55(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">31216723</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem. 1998 May;44(5):1056-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9590385</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Res Toxicol. 2016 Dec 19;29(12):1956-1975</Citation><ArticleIdList><ArticleId IdType="pubmed">27629808</ArticleId></ArticleIdList></Reference><Reference><Citation>Haematologica. 2020 Aug;105(8):2056-2070</Citation><ArticleIdList><ArticleId IdType="pubmed">31780628</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2018 Oct 16;9:2345</Citation><ArticleIdList><ArticleId IdType="pubmed">30459754</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Tissue Res. 2016 Sep;365(3):563-81</Citation><ArticleIdList><ArticleId IdType="pubmed">27324127</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Apr 26;296(5568):695-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11976443</ArticleId></ArticleIdList></Reference><Reference><Citation>Metabolism. 2009 Dec;58(12):1688-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19616266</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2020 Feb;34(2):2749-2764</Citation><ArticleIdList><ArticleId IdType="pubmed">31908042</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2019;1161:45-64</Citation><ArticleIdList><ArticleId IdType="pubmed">31562621</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Dev Biol. 2015;59(1-3):131-40</Citation><ArticleIdList><ArticleId IdType="pubmed">26374534</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2018 Jan 25;13(1):e0191676</Citation><ArticleIdList><ArticleId IdType="pubmed">29370247</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biochem. 2017 Oct;434(1-2):171-179</Citation><ArticleIdList><ArticleId IdType="pubmed">28474284</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2011 Sep 8;30(36):3887-99</Citation><ArticleIdList><ArticleId IdType="pubmed">21499310</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplant Rev (Orlando). 2012 Apr;26(2):88-102</Citation><ArticleIdList><ArticleId IdType="pubmed">22000661</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2012 Jun 22;12(7):479-91</Citation><ArticleIdList><ArticleId IdType="pubmed">22728526</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 1994;12:991-1045</Citation><ArticleIdList><ArticleId IdType="pubmed">8011301</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Plant Sci. 2014 Oct 31;5:578</Citation><ArticleIdList><ArticleId IdType="pubmed">25400647</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2011 Nov 15;187(10):5408-18</Citation><ArticleIdList><ArticleId IdType="pubmed">22013115</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2019 Oct 30;9(1):15660</Citation><ArticleIdList><ArticleId IdType="pubmed">31666644</ArticleId></ArticleIdList></Reference><Reference><Citation>Biophys Rev. 2018 Dec;10(6):1617-1629</Citation><ArticleIdList><ArticleId IdType="pubmed">30382555</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2018 Sep 10;9:1015</Citation><ArticleIdList><ArticleId IdType="pubmed">30250432</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2006 Oct;5(10):821-34</Citation><ArticleIdList><ArticleId IdType="pubmed">17016423</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2015 Mar 1;194(5):2330-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25637017</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Res. 2016 Jun 24;119(1):91-112</Citation><ArticleIdList><ArticleId IdType="pubmed">27340270</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplant Rev (Orlando). 2012 Apr;26(2):73-87</Citation><ArticleIdList><ArticleId IdType="pubmed">22074784</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2017 Apr;31(4):1273-1288</Citation><ArticleIdList><ArticleId IdType="pubmed">28087575</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Drugs Ther. 2020 Feb;34(1):123-131</Citation><ArticleIdList><ArticleId IdType="pubmed">32062794</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatology. 2016 Nov;64(5):1699-1710</Citation><ArticleIdList><ArticleId IdType="pubmed">27474782</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res. 2016 Sep;111:534-544</Citation><ArticleIdList><ArticleId IdType="pubmed">27378565</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2018 Aug 31;128(9):3727-3735</Citation><ArticleIdList><ArticleId IdType="pubmed">30168805</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2018 Nov 7;24(41):4622-4634</Citation><ArticleIdList><ArticleId IdType="pubmed">30416310</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Trauma Emerg Surg. 2020 Aug;46(4):751-775</Citation><ArticleIdList><ArticleId IdType="pubmed">31612270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2013;3:1940</Citation><ArticleIdList><ArticleId IdType="pubmed">23736886</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Cell Cardiol. 2014 May;70:74-82</Citation><ArticleIdList><ArticleId IdType="pubmed">24321195</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2018 Aug 15;9(1):3261</Citation><ArticleIdList><ArticleId IdType="pubmed">30111884</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2016 Sep 14;36(37):9590-603</Citation><ArticleIdList><ArticleId IdType="pubmed">27629711</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Vaccine Res. 2015 Jan;4(1):23-45</Citation><ArticleIdList><ArticleId IdType="pubmed">25648619</ArticleId></ArticleIdList></Reference><Reference><Citation>Antioxid Redox Signal. 2016 Apr 20;24(12):620-34</Citation><ArticleIdList><ArticleId IdType="pubmed">26715031</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2011 Jul 17;17(8):996-1002</Citation><ArticleIdList><ArticleId IdType="pubmed">21765404</ArticleId></ArticleIdList></Reference><Reference><Citation>Environ Health Perspect. 2013 Apr;121(4):405-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23380895</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intern Med. 2019 Jul;286(1):2-15</Citation><ArticleIdList><ArticleId IdType="pubmed">30623510</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 2006 Jun;58(2):259-79</Citation><ArticleIdList><ArticleId IdType="pubmed">16714488</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2012 Nov 26;3:349</Citation><ArticleIdList><ArticleId IdType="pubmed">23189080</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2013 Jul;27(7):2573-83</Citation><ArticleIdList><ArticleId IdType="pubmed">23504711</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chin Med Assoc. 2013 Sep;76(9):486-90</Citation><ArticleIdList><ArticleId IdType="pubmed">23769883</ArticleId></ArticleIdList></Reference><Reference><Citation>Environ Health Perspect. 2006 Jul;114(7):A398</Citation><ArticleIdList><ArticleId IdType="pubmed">16835037</ArticleId></ArticleIdList></Reference><Reference><Citation>EBioMedicine. 2019 Aug;46:264-273</Citation><ArticleIdList><ArticleId IdType="pubmed">31345784</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Physiol. 2010 Nov;225(3):631-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20635395</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma Acute Care Surg. 2018 Aug;85(2):354-358</Citation><ArticleIdList><ArticleId IdType="pubmed">30080781</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Today. 2012 Feb;17 Suppl:S24-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22155646</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Public Health. 2017 Mar 20;38:279-294</Citation><ArticleIdList><ArticleId IdType="pubmed">28068484</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiat Oncol. 2019 May 10;14(1):78</Citation><ArticleIdList><ArticleId IdType="pubmed">31077235</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2010 Oct 22;330(6003):460-1</Citation><ArticleIdList><ArticleId IdType="pubmed">20966241</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Res. 2012 Jan 6;110(1):159-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22223212</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2015 Nov 20;6:588</Citation><ArticleIdList><ArticleId IdType="pubmed">26635802</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2016 Aug 24;8(353):353ra111</Citation><ArticleIdList><ArticleId IdType="pubmed">27559094</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Drug Targets. 2019;20(14):1474-1485</Citation><ArticleIdList><ArticleId IdType="pubmed">31215389</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Clin Immunol. 2012 May;8(4):311-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22607177</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2017 Jan;45(1):58-68</Citation><ArticleIdList><ArticleId IdType="pubmed">27632672</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2015 Feb 1;194(3):863-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25539814</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Transplant. 2016 Dec;16(12):3322-3337</Citation><ArticleIdList><ArticleId IdType="pubmed">27529775</ArticleId></ArticleIdList></Reference><Reference><Citation>Coron Artery Dis. 2015 Jun;26(4):296-300</Citation><ArticleIdList><ArticleId IdType="pubmed">25714070</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Ther Targets. 2016;20(2):223-39</Citation><ArticleIdList><ArticleId IdType="pubmed">26420647</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Cardiol. 2010 Jan;7(1):30-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19949426</ArticleId></ArticleIdList></Reference><Reference><Citation>Q J Nucl Med Mol Imaging. 2016 Sep;60(3):236-51</Citation><ArticleIdList><ArticleId IdType="pubmed">27225319</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Aspects Med. 2019 Feb;65:70-99</Citation><ArticleIdList><ArticleId IdType="pubmed">30056242</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2018 Jul 2;128(7):2657-2669</Citation><ArticleIdList><ArticleId IdType="pubmed">29757195</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2019 Oct 15;13:466</Citation><ArticleIdList><ArticleId IdType="pubmed">31680874</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Cell Mol Biol. 2019;344:31-89</Citation><ArticleIdList><ArticleId IdType="pubmed">30798990</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2019 Mar 26;9(1):5220</Citation><ArticleIdList><ArticleId IdType="pubmed">30914716</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Biosci (Schol Ed). 2013 Jan 01;5:86-104</Citation><ArticleIdList><ArticleId IdType="pubmed">23277038</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbiol Spectr. 2016 Jun;4(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">27337457</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2014 Feb;28(2):836-48</Citation><ArticleIdList><ArticleId IdType="pubmed">24249635</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Immunopharmacol. 2020 Mar;80:106134</Citation><ArticleIdList><ArticleId IdType="pubmed">31931365</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Rev Med Pharmacol Sci. 2015 Jun;19(12):2221-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26166646</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2012 Oct 11;120(15):e60-72</Citation><ArticleIdList><ArticleId IdType="pubmed">22904297</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Cell. 2018 May 14;33(5):862-873.e5</Citation><ArticleIdList><ArticleId IdType="pubmed">29706455</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2018 Apr 16;19(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">29659553</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplantation. 1994 Jan;57(2):211-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8310510</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):220</Citation><ArticleIdList><ArticleId IdType="pubmed">31924786</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Ther Targets. 2018 Mar;22(3):263-277</Citation><ArticleIdList><ArticleId IdType="pubmed">29447008</ArticleId></ArticleIdList></Reference><Reference><Citation>Biofactors. 2013 Jul-Aug;39(4):355-67</Citation><ArticleIdList><ArticleId IdType="pubmed">23900966</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Clin. 2017 Jan;33(1):167-191</Citation><ArticleIdList><ArticleId IdType="pubmed">27894496</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2019 Apr 02;10:252</Citation><ArticleIdList><ArticleId IdType="pubmed">31001110</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Aspects Med. 2017 Dec;58:12-20</Citation><ArticleIdList><ArticleId IdType="pubmed">28365269</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2016 Mar 15;44(3):450-462</Citation><ArticleIdList><ArticleId IdType="pubmed">26982353</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2015;11(2):477-88</Citation><ArticleIdList><ArticleId IdType="pubmed">25692535</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncoimmunology. 2012 Aug 1;1(5):786-788</Citation><ArticleIdList><ArticleId IdType="pubmed">22934283</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Genet. 2011 May;12(5):329-40</Citation><ArticleIdList><ArticleId IdType="pubmed">21499294</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2018 Jun 28;61(12):5093-5107</Citation><ArticleIdList><ArticleId IdType="pubmed">29268019</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Sci (Lond). 2019 Nov 15;133(21):2121-2141</Citation><ArticleIdList><ArticleId IdType="pubmed">31693730</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2018 Nov 20;9:2619</Citation><ArticleIdList><ArticleId IdType="pubmed">30515151</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>France</li></country><region><li>Alsace (région administrative)</li><li>Bavière</li><li>District de Haute-Bavière</li><li>Grand Est</li></region><settlement><li>Munich</li><li>Strasbourg</li></settlement></list><tree><country name="France"><region name="Grand Est"><name sortKey="Land, Walter Gottlieb" sort="Land, Walter Gottlieb" uniqKey="Land W" first="Walter Gottlieb" last="Land">Walter Gottlieb Land</name></region></country><country name="Allemagne"><region name="Bavière"><name sortKey="Land, Walter Gottlieb" sort="Land, Walter Gottlieb" uniqKey="Land W" first="Walter Gottlieb" last="Land">Walter Gottlieb Land</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000291 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000291 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32248387
|texte= Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32248387" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |